Hi-Tech Pharmacal Co. Wednesday said it would comply with a federal warning about labels on three of its medicinal creams for diabetics.
The Amityville-based manufacturer of generic and brand-name drugs said it had received a “warning letter” from the federal Food and Drug Administration on July 15. The letter “related to certain statements that appear in labeling” on the creams, the company said.
The creams are Diabeti-Derm Antifungal Cream and Zostrix Diabetic Foot Pain Relief Cream and Diabetic Joint & Arthritis Pain Relief Cream.
The three products generated $1.1 million in sales for the fiscal year ended April 30. Hi-Tech’s total sales for the year were $232 million.
Wednesday’s announcement came before the stock markets’ opening. In early trading, Hi-Tech shares were down 25 cents, or less than 1 percent, to $36.33.